Pharmacogenomics in early-phase clinical development

Pharmacogenomics

Volumn 14, Issue 9, 2013, Pages 1085-1097

  Burt, Tal ^a   Dhillon, Savita ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Medanta Duke Research Institute (MDRI)   (India)

Author keywords

Clinical research; Drug development; Early phase; PD; PGt; PGx; Pharmacodynamics; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics; PK; POC; Proof of concept

Indexed keywords

ABACAVIR; CLOPIDOGREL; CODEINE; GEFITINIB; IRINOTECAN; IVACAFTOR; MERCAPTOPURINE; TRASTUZUMAB; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL RESEARCH; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DRUG DESIGN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE POLICY; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PAIN; PHARMACOGENOMICS; PROGRAM DEVELOPMENT; REVIEW; THROMBOEMBOLISM; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84880453290     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.81     Document Type: Review

References (107)

1. ICH. E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2008
2. Kalow W. Human pharmacogenomics: The development of a science. Hum. Genomics 1(5), 375-380 (2004
3. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7, 223-245 (2006
4. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: Translating science into practice. Clin. Pharmacol. Ther. 92(4), 467-475 (2012
5. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286(5439), 487-491 (1999
6. Ohashi W, Tanaka H. Benefits of pharmacogenomics in drug developmentearlier launch of drugs and less adverse events. J. Med. Syst. 34(4), 701-707 (2010
7. Powanda MC, Moyer ED. Some applications of pharmacogenomics and epigenetics in drug development and use in pursuit of personalized medicine. Inflammopharmacology 20(5), 245-250 (2012
8. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat. Rev. Genet. 4(12), 937-947 (2003
9. Milos PM, Seymour AB. Emerging strategies and applications of pharmacogenomics. Hum. Genomics 1(6), 444-455 (2004
10. US FDA. Guidance for Industry. Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH) (2011
11. Collins FS. Reengineering translational science: The time is right. Sci. Transl. Med. 3(90), 90cm17 (2011
12. US FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. US Department of Health and Human Services, US FDA (2004
13. Lesko LJ, Schmidt S. Individualization of drug therapy: History, present state, and opportunities for the future. Clin. Pharmacol. Ther. 92(4), 458-466 (2012
14. Roberti di Sarsina P, Ottaviani L, Mella J. Tibetan medicine: A unique heritage of person-centered medicine. EPMA J. 2(4), 385-389 (2011
15. Sumantran VN, Tillu G. Insights on personalized medicine from Ayurveda. J. Altern. Complement. Med. 19(4), 370-375 (2013
16. Meletis J, Konstantopoulos K. Favism-from the 'avoid fava beans' of pythagoras to the present. Haema 7(1), 17-21 (2004
17. Sukumar S, Colah R, Mohanty D. G6PD gene mutations in India producing drug-induced haemolytic anaemia. Br. J. Haematol. 116(3), 671-672 (2002
18. Nasser M, Tibi A, Savage-Smith E. Ibn Sina's canon of medicine: 11th century rules for assessing the effects of drugs. J. R. Soc. Med. 102(2), 78-80 (2009
19. Ghodke Y, Joshi K, Patwardhan B. Traditional medicine to modern pharmacogenomics: Ayurveda prakriti type and CYP2C19 gene polymorphism associated with the metabolic variability. Evid. Based Complement. Alternat. Med. 2011, 249528 (2011
20. Motulsky AG. Drug reactions enzymes, and biochemical genetics. J. Am. Med. Assoc. 165(7), 835-837 (1957
21. Motulsky A. From pharmacogenetics and ecogenetics to pharmacogenomics. Med. Secoli. 14(3), 683-705 (2002
22. Gurwitz D, Motulsky AG. 'Drug reactions, enzymes, and biochemical genetics': 50 years later. Pharmacogenomics 8(11), 1479-1484 (2007
23. Vesell ES, Page JG. Genetic control of dicumarol levels in man. J. Clin. Invest. 47(12), 2657-2663 (1968
24. Lemmens HJ, Stanski DR. Individualized dosing with anesthetic agents. Clin. Pharmacol. Ther. 92(4), 417-419 (2012
25. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a Phase 1 trial of the anti- CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355(10), 1018-1028 (2006
26. Kenter MJ, Cohen AF. Establishing risk of human experimentation with drugs: Lessons from TGN1412. Lancet 368(9544), 1387-1391 (2006
27. Myrand SP, Sekiguchi K, Man MZ et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther. 84(3), 347-361 (2008
28. Relling MV, Gardner EE, Sandborn WJ et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89(3), 387-391 (2011
29. Armour AA, Watkins CL. The challenge of targeting EGFR: Experience with gefitinib in nonsmall cell lung cancer. Eur. Respir. Rev. 19(117), 186-196 (2010
30. Kahn J. Exploiting race in drug development: BiDil's interim model of pharmacogenomics. Soc. Stud. Sci. 38(5), 737-758 (2008
31. Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA. Implications of pharmacogenomics for drug development and clinical practice. Arch. Intern. Med. 165(20), 2331-2336 (2005
32. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: A critical and systematic review. Pharmacoeconomics 28(11), 1001-1013 (2010
33. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010
34. Wang L, Weinshilboum RM. Pharmacogenomics: Candidate gene identification, functional validation and mechanisms. Hum. Mol. Genet. 17(R2), R174-R179 (2008
35. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat. Biotechnol. 30(11), 1117-1124 (2012
36. Bush WS, Moore JH. Chapter 11: Genome-wide association studies. PLoS Comput. Biol. 8(12), e1002822 (2012
37. Giacomini KM, Yee SW, Ratain MJ, Weinshilboum RM, Kamatani N, Nakamura Y. Pharmacogenomics and patient care: One size does not fit all. Sci. Transl. Med. 4(153), 153ps118 (2012
38. Reynolds KS. Achieving the promise of personalized medicine. Clin. Pharmacol. Ther. 92(4), 401-405 (2012
39. Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta 1770(3), 489-494 (2007
40. Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5), 442-473 (2004
41. Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin. Lab. Med. 28(4), 619-626 (2008
42. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14), 1273-1283 (2011
43. Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: A basis for dose individualization. Clin. Pharmacokinet. 47(9), 565-594 (2008
44. Olivier C, Williams-Jones B. Pharmacogenomic technologies: A necessary 'luxury' for better global public health? Global Health 7(1), 30 (2011
45. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice? Nat. Rev. Drug Discov. 4(8), 639-647 (2005
46. Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatry-a useful clinical tool or wishful thinking for the future? Curr. Pharm. Des. 16(2), 136-144 (2010
47. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. Implementing personalized medicine: Development of a cost-effective customized pharmacogenetics genotyping array. Clin. Pharmacol. Ther. 92(4), 437-439 (2012
48. Frueh FW, Amur S, Mummaneni P et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: Prevalence of related drug use. Pharmacotherapy 28(8), 992-998 (2008
49. Relling MV, Klein TE. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89(3), 464-467 (2011
50. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92(4), 414-417 (2012
51. Takarabe M, Kotera M, Nishimura Y, Goto S, Yamanishi Y. Drug target prediction using adverse event report systems: A pharmacogenomic approach. Bioinformatics 28(18), i611-i618 (2012
52. O'Donnell PH, Stadler WM. Pharmacogenomics in early-phase oncology clinical trials: Is there a sweet spot in Phase II? Clin. Cancer Res. 18(10), 2809-2816 (2012
53. Giacomini KM, Huang SM, Tweedie DJ et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9(3), 215-236 (2010
54. Yan Q. Membrane transporters and drug development: Relevance to pharmacogenomics, nutrigenomics, epigenetics, and systems biology. Methods Mol. Biol. 637, 1-21 (2010
55. Delezie J, Challet E. Interactions between metabolism and circadian clocks: Reciprocal disturbances. Ann. NY Acad. Sci. 1243, 30-46 (2011
56. Bartfai T. Pharmacogenomics in drug development: Societal and technical aspects. Pharmacogenomics J. 4(4), 226-232 (2004
57. Eisenberg RS. Will pharmacogenomics alter the role of patents in drug development? Pharmacogenomics 3(5), 571-574 (2002
58. Ferentz AE. Integrating pharmacogenomics into drug development. Pharmacogenomics 3(4), 453-467 (2002
59. Guo Y, Shafer S, Weller P, Usuka J, Peltz G. Pharmacogenomics and drug development. Pharmacogenomics 6(8), 857-864 (2005
60. Iqbal O. Pharmacogenomics in anticoagulant drug development. Pharmacogenomics 3(6), 823-828 (2002
61. Johnson K, Thompson J, Power A. Pharmacogenomics: Integration into drug discovery and development. Curr. Top. Med. Chem. 5(11), 1039-1046 (2005
62. Kirk RJ, Hung JL, Horner SR, Perez JT. Implications of pharmacogenomics for drug development. Exp. Biol. Med. 233(12), 1484-1497 (2008
63. Ledley FD. Can pharmacogenomics make a difference in drug development? Nat. Biotechnol. 17(8), 731 (1999
64. Lee W, Lockhart AC, Kim RB, Rothenberg ML. Cancer pharmacogenomics: Powerful tools in cancer chemotherapy and drug development. Oncologist 10(2), 104-111 (2005
65. Leeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov. Today 9(13), 567-573 (2004
66. Lindpaintner K. Pharmacogenetics and pharmacogenomics in drug discovery and development: An overview. Clin. Chem. Lab. Med. 41(4), 398-410 (2003
67. Liou SY, Stringer F, Hirayama M. The impact of pharmacogenomics research on drug development. Drug Metab. Pharmacokinet. 27(1), 2-8 (2012
68. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and clinical biomarkers in drug discovery and development. Am. J. Clin. Pathol. 124(Suppl.), S29-S41 (2005
69. Stingl Kirchheiner JC, Brockmoller J. Why, when, and how should pharmacogenetics be applied in clinical studies?: Current and future approaches to study designs. Clin. Pharmacol. Ther. 89(2), 198-209 (2011
70. Stormer E, von Moltke LL, Greenblatt DJ. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J. Pharmacol. Exp. Ther. 295(2), 793-801 (2000
71. Daly AK, Donaldson PT, Bhatnagar P et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41(7), 816-819 (2009
72. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N. Engl. J. Med. 358(6), 637-639 (2008
73. Dickinson GL, Rezaee S, Proctor NJ, Lennard MS, Tucker GT, Rostami-Hodjegan A. Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: Dextromethorphan as a model application. J. Clin. Pharmacol. 47(2), 175-186 (2007
74. Yengi LG, Xiang Q, Shen L, Chandrasekaran A, Kao J, Scatina J. Application of pharmacogenomics in drug discovery and development: Correlations between transcriptional modulation and preclinical safety observations. Drug Metab. Lett. 1(1), 41-48 (2007
75. Grady BJ, Ritchie MD. Statistical optimization of pharmacogenomics association studies: Key considerations from study design to analysis. Curr. Pharmacogenomics Person. Med. 9(1), 41-66 (2011
76. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011
77. Ieiri I, Doi Y, Maeda K et al. Microdosing clinical study: Pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J. Clin. Pharmacol. 52(7), 1078-1089 (2012
78. Ieiri I, Nishimura C, Maeda K et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet. Genomics 21(8), 495-505 (2011
79. Maeda K, Sugiyama Y. Novel strategies for microdose studies using non-radiolabeled compounds. Adv. Drug Deliv. Rev. 63(7), 532-538 (2011
80. Wagner CC, Langer O. Approaches using molecular imaging technology-use of PET in clinical microdose studies. Adv. Drug Deliv. Rev. 63(7), 539-546 (2011
81. US FDA. Guidance for Industry, Investigators, and Reviewers. Exploratory IND Studies. US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research (CDER) (2006
82. Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, Evans WE. Cancer pharmacogenomics. Clin. Pharmacol. Ther. 90(3), 461-466 (2011
83. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91(2), 321-326 (2012
84. Verhoef TI, Redekop WK, van Schie RM et al. Cost-effectiveness of pharmacogenetics in anticoagulation: International differences in healthcare systems and costs. Pharmacogenomics 13(12), 1405-1417 (2012
85. US FDA. Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug (2010
86. Piana C, Surh L, Furst-Recktenwald S et al. Integration of pharmacogenetics and pharmacogenomics in drug development: Implications for regulatory and medical decision making in pediatric diseases. J. Clin. Pharmacol. 52(5), 704-716 (2012
87. Surh LC, Pacanowski MA, Haga SB et al. Learning from product labels and label changes: How to build pharmacogenomics into drug-development programs. Pharmacogenomics 11(12), 1637-1647 (2010
88. Salerno RA, Lesko LJ. Pharmacogenomics in drug development and regulatory decisionmaking: The Genomic Data Submission (GDS) Proposal. Pharmacogenomics 5(1), 25-30 (2004
89. Cook J, Hunter G, Vernon JA. The future costs, risks and rewards of drug development: The economics of pharmacogenomics. Pharmacoeconomics 27(5), 355-363 (2009
90. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363(4), 301-304 (2010
91. Marsh S, King CR, Porche-Sorbet RM, Scott- Horton TJ, Eby CS. Population variation in VKORC1 haplotype structure. J. Thromb. Haemost. 4(2), 473-474 (2006
92. Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009
93. Moja L, Tagliabue L, Balduzzi S et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst. Rev. 4, CD006243 (2012
94. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008
95. Ramsey BW, Davies J, McElvaney NG et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365(18), 1663-1672 (2011
96. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: Practical pharmacogenomics arrives in cancer therapy. J. Clin. Oncol. 24(28), 4534-4538 (2006
97. Balram C, Sabapathy K, Fei G, Khoo KS, Lee EJ. Genetic polymorphisms of UDPglucuronosyltransferase in Asians: UGT1A1.*28 is a common allele in Indians. Pharmacogenetics 12(1), 81-83 (2002
98. Meisel C, Gerloff T, Kirchheiner J et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J. Mol. Med. 81(3), 154-167 (2003
99. Lai Y, Varma M, Feng B et al. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability-considerations for drug development. Expert Opin. Drug Metab. Toxicol. 8(6), 723-743 (2012
100. van Schie RM, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009
101. Laskowitz DT, Vitek MP. Apolipoprotein E and neurological disease: Therapeutic potential and pharmacogenomic interactions. Pharmacogenomics 8(8), 959-969 (2007
102. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2008
103. Frueh FW. Back to the future: Why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Pharmacogenomics 10(7), 1077-1081 (2009
104. Prasad K. Role of regulatory agencies in translating pharmacogenetics to the clinics. Clin. Cases Miner. Bone Metab. 6(1), 29-34 (2009
105. Fleck LM. Pharmacogenomics and personalized medicine: Wicked problems, ragged edges and ethical precipices. N. Biotechnol. 29(6), 757-768 (2012
106. Wertz DC. Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J. 3(4), 194-196 (2003
107. Peterson-Iyer K. Pharmacogenomics, ethics, and public policy. Kennedy Inst. Ethics J. 18(1), 35-56 (2008